Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder

Figures & data

Table 1 Comparison of discontinuation of PAX treatment between patients with PD and MDD

	Discontinued, n (%)
Total discontinuation rate
PD	15/52 (28.8)
MDD	17/88 (19.3)
Discontinuation rate due to nonadherence
PD	7/52 (13.5)**,¶
MDD	0/88 (0)**,¶
Discontinuation rate due to adverse effects
PD	7/52 (13.5)
MDD	6/88 (6.8)
Discontinuation rate due to untraceability
PD	1/52 (1.9)*,¶
MDD	11/88 (12.5)*,¶

Notes:

¶ Fisher’s exact test.

* P<0.05.

** P<0.001.

Abbreviations: PD, panic disorder; MDD, major depressive disorder; PAX, paroxetine.

Table 2 Demographic characteristics of PD patients at baseline, according to 5-HTTLPR genotype

	5-HTT gene-linked polymorphic region		Total
Genotype	L/S genotype	S/S genotype
# of patients	20	32	52
Male/female, n	9/11	11/21	20/32
Age, years	36.0±6.5	32.7±9.2	33.9±8.3
Body weight, kg	62.3±12.8	55.1±9.7	57.9±11.4
With/without agoraphobia, n	13/7	26/6	39/13
Panic attacks per week, n	2.7±2.5	2.9±3.7	2.8±3.2
Panic and Agoraphobia Scale score	20.5±7.5	22.2±5.8	21.5±6.5

Notes: Values are numbers of subjects or mean ± SD.

Abbreviations: PD, panic disorder; L/S, long/short; S/S, short/short; SD, standard deviation.

Table 3 Discontinuation of pharmacotherapy with PAX at 2 weeks after initiation, according to 5-HTTLPR genotype in PD patients

	Discontinued
Total discontinuation rate
L/S genotype	8 (8/20=40%)
S/S genotype	7 (7/32=21.9%)
Discontinuation rate due to nonadherence
L/S genotype	3 (3/20=15%)¶
S/S genotype	4 (4/32=12.5%)¶
Discontinuation rate due to adverse effects
L/S genotype	5 (5/20=25.0%)*,¶
S/S genotype	2 (2/32=6.3%)*,¶
Discontinuation rate due to untraceability
L/S genotype	0 (0/20=0%)¶
S/S genotype	1 (1/32=3.1%)¶

Notes:

¶ Fisher’s exact test.

* P=0.067.

Abbreviations: PAX, paroxetine; PD, panic disorder; L/S, long/short; S/S, short/short.

Table 4 Demographic characteristics of MDD patients at baseline, according to 5-HTTLPR genotype

	5-HTTLPR		Total
Genotype	L/S genotype	S/S genotype
# of patients	31	57	88
Male/female, n	10/21	19/38	29/59
Age, years	46.0±12.6	47.3±14.2	46.8±13.6
Body weight, kg	56.7±9.1	56.0±10.5	56.3±10.0
MADRS score	40.5±9.3	38.0±9.5	38.9±9.5

Note: Values are numbers or mean ± SD.

Abbreviations: MDD, major depressive disorder; MADRS: Montgomery–Åsberg Depression Rating Scale; SD, standard deviation; L/S, long/short; S/S, short/short.

Table 5 Discontinuation of pharmacotherapy with PAX at 2 weeks after initiation, according to 5-HTTLPR genotype in MDD patients

	Discontinued
Total discontinuation rate
L/S genotype	4 (4/31=12.9%)¶
S/S genotype	13 (13/57=22.8%)¶
Discontinuation rate due to nonadherence
L/S genotype	0 (0/31=0%)¶
S/S genotype	0 (0/57=0%)¶
Discontinuation rate due to adverse effects
L/S genotype	1 (1/31=3.2%)¶
S/S genotype	5 (5/57=8.8%)¶
Discontinuation rate due to untraceability
L/S genotype	3 (3/31=9.7%)¶
S/S genotype	8 (8/57=14.0%)¶

Note:

¶ Fisher’s exact test.

Abbreviations: PAX, paroxetine; MDD, major depressive disorder; L/S, long/short; S/S, short/short.